HT-29 Cells

The HT-29 cell line, derived from a Grade II human colorectal adenocarcinoma, represents a cornerstone research model in the study of human colon cancers. Derived from a primary tumor in a 44-year-old female in 1964, HT22 cells have been instrumental in advancing our understanding of the adhesion or invasion mechanisms of cancer cells. As a human adenocarcinoma cell line, HT-29 cells exhibit characteristics that closely mimic those of mature intestinal cells, such as enterocytes, underscoring their utility in exploring the dynamics of food digestion and nutrient bioavailability.
HT-29 cells are sensitive to conventional colorectal cancer chemotherapies, including 5-fluorouracil and oxaliplatin. This sensitivity, coupled with their ability to express differentiation pathways under specific conditions, such as glucose deprivation or treatment with inducers like butyrate, makes them an invaluable model for investigating the molecular mechanisms underlying cell differentiation and cancer progression.
Moreover, HT-29 cells have been utilized as a xenograft tumor model, providing a platform for in vivo studies that mimic the tumor’s behavior in the human body. This application allows for the exploration of tumor growth, metastasis, and the efficacy of therapeutic agents in in vivo situations.
In summary, the HT-29 cell line is a pivotal tool in medical and biological research, facilitating a deeper understanding of human colon adenocarcinoma, the molecular basis of cancer cell differentiation, and the development of effective cancer treatments.